Quarterly report pursuant to Section 13 or 15(d)

4. Commitments and Contingencies (Narrative)

v2.4.0.8
4. Commitments and Contingencies (Narrative) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Mar. 31, 2013
Potential severance under certain employment agreements $ 1,843   $ 1,843    
Aggregated annual salaries under certain employment agreements 1,310   1,310    
Product revenue 2,450 2,655 8,627 10,312  
Milestone payment as revenue 629 702 1,459 1,125  
More Pharma
         
Accounts receivable 1,129   1,129   580
Amortization of upfront fees (transaction costs) 379 379 1,131 569  
Vetericyn and Innovacyn
         
Accounts receivable 340   340   264
Product revenue 652 883 2,682 3,248  
AmDerma
         
Milestone payment as revenue $ 250   $ 250